Company / FCF Margin
Theravance Biopharma, Inc. FCF Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
221.9%
FY2025
5-year range
-382.0% / 221.9%
FY2021-FY2025
Trend
+1304.2%
vs FY2024
Sector context
#2 of 134
Health Care
What the data says
FCF Margin changed +1304% YoY in FY2025, a notable deviation from the 9-year average annual change of -220%.
Based on SEC 10-K filings.
221.9% in FY2025 with a 5-year CAGR of +579.6%. Ranks 2nd among 134 companies in Health Care.
Improved from -51.3% to 221.9% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- +579.6pp
- 5-Year Change
- +579.6pp
- 10-Year Change
- -
Sector benchmark
Top 1% in Health CareTop 1% of 134This company 221.9% Sector average -637.8%
▼
+134.8% above sector average
Key checks
Key Insights
- Theravance Biopharma, Inc.'s fcf margin has grown for 4 consecutive years.
- In FY2025, fcf margin increased 1304.2% year-over-year.
- Currently 859.7pp above the Health Care sector average.
- Lowest fcf margin in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 221.9% | +1304.2% |
| FY2024 | -18.4% | +64.1% |
| FY2023 | -51.3% | +85.6% |
| FY2022 | -357.7% | +6.4% |
| FY2021 | -382.0% | -6.8% |
| FY2020 | -357.7% | +73.0% |
| FY2019 | -1322.4% | -536.1% |
| FY2018 | -207.9% | +96.8% |
| FY2017 | -6590.8% | -3070.6% |
| FY2016 | -207.9% | +99.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026